Related Experiment Videos
Learning from failure: congestive heart failure in the postgenomic age
Ivor J Benjamin1, Michael D Schneider
1Division of Cardiology, Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah 84132, USA. ivor.benjamin@hsc.utah.edu
The Journal of Clinical Investigation
|March 15, 2005
Summary
New cell therapies and repurposed drugs offer hope for heart failure, a condition with a poor prognosis. Research using genetically engineered models is accelerating discoveries for acquired and inheritable cardiac diseases.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Genetics
Background:
- Heart failure presents a significant challenge with a worse prognosis than most cancers.
- Traditional treatments have limitations, necessitating novel therapeutic approaches.
Purpose of the Study:
- To highlight advancements in heart failure treatment.
- To discuss the role of cell-based therapies and repurposed drugs.
- To explore the contribution of genetically engineered animal models to understanding cardiac diseases.
Main Methods:
- Review of current therapeutic interventions, including stem and cell-based therapies.
- Analysis of the impact of genetically engineered animal models on research.
- Investigation into molecular mechanisms underlying heart failure.
Main Results:
- Cell-based therapies are showing success in treating heart failure.
- Repurposed drugs are demonstrating renewed efficacy.
- Genetically engineered models are crucial for understanding disease mechanisms and accelerating drug discovery.
Conclusions:
- Emerging cell therapies and innovative drug strategies are improving heart failure prognosis.
- Genetically engineered animal models are vital for advancing treatments for acquired and inheritable cardiac conditions.